Erasca (ERAS) investor relations material

Company overview and strategy

• Focuses on precision oncology targeting the RAS-MAP kinase pathway, mutated in up to half of all cancers.

• Well-capitalized with $362 million in cash as of Q3, providing runway through the second half of 2028.

• Aggressive clinical development plan enabled by strong financial and human capital.

• Pipeline includes pan-RAS (ERAS-0015), pan-KRAS (ERAS-4001), and a discovery-stage bispecific EGFR antibody.

• Strategy includes both monotherapy and combination approaches with standard of care and investigational agents.

Lead programs: ERAS-0015 and ERAS-4001

• ERAS-0015 shows 8-20x better binding affinity to cyclophilin A and 4-5x greater in vitro potency than Revolution Medicines' 6236.

• Demonstrates better in vivo activity at one-tenth the dose and improved PK properties, including clearance and bioavailability.

• ERAS-4001 is a switch-II pocket binder with strong in vitro potency against G12X, G13, and KRAS wild type mutations.

• Features a unique chemical scaffold, potentially bypassing issues seen with other molecules.

• Both programs are in phase one dose escalation, with INDs cleared in May and enrollment progressing well.

Clinical development and trial design

• Phase one trials for both programs are enrolling all comers with RAS mutations, with the ability to enrich for specific populations later.

• Four to five sites per program, with minimal overlap to optimize enrollment.

• Initial data readouts for both programs are guided for calendar year 2026, with dozens of patients expected per update.

• Data may be presented at medical meetings or company events, depending on timing.

• For 4001, prior KRAS inhibitor exposure is excluded.